(Q34330606)

1 August 2017

1 reference

title

CTLA4Ig: a novel inhibitor of costimulation (English)

1 reference

1 August 2017

M Dall'Era

1

1 reference

1 August 2017

J Davis

series ordinal

2

1 reference

1 August 2017

publication date

1 January 2004

1 reference

1 August 2017

1 reference

1 August 2017

volume

13

1 reference

1 August 2017

issue

5

1 reference

1 August 2017

page(s)

372-376

1 reference

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1029OA

The role of T-cell costimulatory activation pathways in transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1029OA

Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1029OA

CTLA-4 is a second receptor for the B cell activation antigen B7

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1029OA

Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1029OA

Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1029OA

Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1029OA

CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1029OA

Prolongation of cardiac graft survival with anti-CD4Ig plus hCTLA4Ig in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1029OA

Treatment of murine lupus with CTLA4Ig

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1029OA

CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1029OA

Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1029OA

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1029OA

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1029OA

10.1191/0961203303LU1029OA

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference